Lentiviral vectors pseudotyped with G glycoprotein from vesicular stomatitis virus (VSV-G) and baculovirus gp64 are inactivated by human complement. The extent of vector inactivation in serum from individual donors was examined and results showed wide donor-dependent variation in complement sensitivity for VSV-G-pseudotyped lentivectors. Amphotropic envelope (Ampho)-pseudotyped vectors were generally resistant to serum from all donors, while gp64-pseudotyped vectors were inactivated but showed less donor-to-donor variation than VSV-G. In animal sera, the vectors were mostly resistant to inactivation by rodent complement, whereas canine complement caused a moderate reduction in titer. In a novel advance for the lentiviral vector system, human complement-resistant-pseudotyped lentivector particles were produced through incorporation of complement regulatory proteins (CRPs). Decay accelerating factor (DAF)/CD55 provided the most effective protection using this method, while membrane cofactor protein (MCP)/ CD46 showed donor-dependent protection and CD59 provided little or no protection against complement inactivation. Unlike previous approaches using CRPs to produce complement-resistant viral vectors, CRP-containing lentivectors particles were generated for this study without engineering the CRP molecules. Thus, through overexpression of native DAF/CD55 in the viral producer cell, an easy method was developed for generation of lentiviral vectors that are almost completely resistant to inactivation by human complement. Production of complement-resistant lentiviral particles is a critical step toward use of these vectors for in vivo gene therapy applications. Gene Therapy (2005) 12, 238-245.
Introduction
Two envelope glycoproteins that efficiently pseudotype lentiviral vectors are the G glycoprotein from vesicular stomatitis virus (VSV-G) and gp64 from baculovirus. [1] [2] [3] [4] Both envelope proteins confer physical stability and high infectivity to vector particles and show relatively broad tissue and species tropism. 3, 5 However, a drawback of both glycoproteins is their sensitivity to inactivation by human complement, which may hamper effective use of these pseudotypes in human therapies. 3, 6 Complement inactivation of virus particles has been shown to occur under various conditions and via distinct mechanisms. Virus and vector sensitivity to human serum complement can be dependent on the cell type and species derivation of the cell line used to produce the vectors as well as the identity of the envelope glycoprotein used for pseudotyping. 7, 8 For instance, retroviral vectors produced in murine and canine producer cells are sensitive to inactivation by human complement. [9] [10] [11] The primary trigger of complement attack in these instances is human antibody recognition of the a-1,3-galactosyl (a-Gal) epitope, which is presented on cells from lower mammals but not humans or Old World primates. 7, 8, 12 An example of an envelope protein that induces complement attack is VSV-G. VSV-G-pseudotyped viral vectors, regardless of producer cell type or vector type, will be inactivated by human serum complement, while vectors pseudotyped with other envelope glycoproteins such as the MLV amphotropic envelope (Ampho) or RD114 are resistant to inactivation. 6, 13 Several groups are developing viral vectors based on baculovirus for gene therapy applications.
14 A shortcoming of these vectors is that they are quickly inactivated by human serum and rodent serum, precluding their effective use in vivo. 15, 16 It was proposed that inactivation of these vectors was triggered by human and rodent recognition of insect-specific glycosylation epitopes on the membrane envelope of the vector. 15, 17 However, we recently found that lentiviral vectors produced in human cells and pseudotyped with gp64, the major envelope protein of baculovirus, are still inactivated by serum complement from humans but not rodents. 3 This result indicated that at least some component of baculovirus inactivation in human serum is specific to the gp64 protein and not the insect-derived envelope. Activation of the complement cascade can occur via two general pathways. The classical pathway is usually dependent on complement factor recognition of antigenantibody complexes. VSV and baculovirus are inactivated in human serum via the classical pathway. 16, 18, 19 Retroviruses and retroviral vectors derived from nonhuman producer cells have also been found to be inactivated through the classical pathway, via a-Gal recognition or possibly through an antibody-independent mechanism. [20] [21] [22] Complement attack can also be activated via the alternative pathway, which is triggered by certain nonimmune activators in microbial membranes. Activation of either pathway will usually result in the assembly of proteins to form a transmembrane pore, called the membrane attack complex (MAC), which causes lysis of the cell or virus particle. 23 Complement activity is normally controlled by a number of complement regulatory proteins (CRPs). These proteins prevent spurious inflammation and host tissue damage. One group of proteins, including CD55/ decay accelerating factor (DAF) and CD46/membrane cofactor protein (MCP), inhibits the classical and alternative pathway C3/C5 convertase enzymes. 24, 25 Another set of proteins including CD59 regulates MAC assembly. 26 CRPs have been used to prevent rejection of xenotransplanted tissues and have also been shown to protect viruses and viral vectors from complement inactivation.
One of the major limitations of using lentiviral vectors with VSV-G or gp64 pseudotyping in human clinical applications is their susceptibility to inactivation by human complement. To overcome this problem, we were interested in finding a method to produce complementresistant lentiviral vectors. We first set out to determine the extent and variation of lentiviral vector inactivation by human serum and serum from other relevant animal models. In addition, we tested whether CRPs could be incorporated into lentiviral vector particles and determined the degree of protection that they could confer against complement inactivation. Our results show that CRPs (especially DAF/CD55) are easily incorporated into lentiviral vectors without modification and can confer a significant level of protection against complement attack.
Results
The sensitivity of lentiviral vectors to human complement inactivation is donor-dependent It was previously shown that lentiviral vectors pseudotyped with VSV-G were sensitive to inactivation by pooled human serum, whereas Ampho-pseudotyped vectors were resistant to inactivation. 6 To better determine the average extent of vector inactivation in human patients, the sensitivity of lentiviral vectors to serum complement from individual human donors was examined. Concentrated preparations of lentiviral vectors carrying the GFP transgene and pseudotyped with VSV-G, MLV Ampho or baculovirus gp64 envelope glycoprotein were produced by transient transfection in 293T cells. The vectors were normalized for titer and then exposed to normal or heat-inactivated serum from different human donors. Following serum exposure, the residual titer was quantitated and results are reported as the percentage of recovery of titer compared to control samples that were not exposed to serum. For VSV-G pseudotypes (Figure 1a) , an overall sensitivity to inactivation by human complement was observed, as denoted by the difference in titer recovery after incubation with normal serum versus heat-inactivated serum for each donor (compare hatched versus black bars). Complement-active serum caused a reduction in VSV-G titer for every donor but the extent of inactivation varied. Some donors showed only a several-fold inactivation while another reduced VSV-G titer below the limit of detection (less than 0.05% recovery). The majority of donor sera inactivated the vector between 10-and 100-fold, with several donors causing greater than 100-fold reduction in titer. Unlike VSV-G, there was almost no inactivation of lentiviral vectors pseudotyped with the 6 TU/ml. The vector was then diluted 1:5 into medium (the no-serum control) or human serum that was normal (hatched bars) or heat-inactivated (black bars) from individual single human donors. After a 1-h incubation at 371C, the vectors were tested for end point titers on 293T cells. The titer from vector incubated with the medium control was set as 100% recovery. Bars represent the percentage of titer remaining in the vector samples after incubation with normal or heat-inactivated serum compared to vector incubated with the medium control (100%).
Complement-resistant lentiviral vectors C Schauber-Plewa et al MLV Ampho (Figure 1b ). For most donors there was no reduction in Ampho titer, whereas slight inactivation was observed in serum from two donors. Like VSV-G vectors, the gp64-pseudotyped lentiviral vectors were sensitive to inactivation by the human sera (Figure 1c ), with 15-to 100-fold reductions in titer for gp64 pseudotypes in serum from individual donors. As a control for these studies, the human serum samples were tested for hemolytic complement activity (CH 50 ) and all were found to be in the normal range (Figure 2) . Thus, VSV-G-and gp64-pseudotyped vectors were significantly inactivated by the human sera, with VSV-G sensitivity showing more donor-dependent fluctuation.
The experiments shown in Figure 1 were carried out with lentiviral vectors that were generated by transient cotransfection of four plasmids. It is very likely that viral vectors produced in the future will be made with stable producer cell lines, and that differences in membrane proteins and/or VSV-G expression might alter the complement sensitivity of the vectors. To determine whether stably produced lentiviral vectors are sensitive to complement inactivation, we tested vector particles produced in a stable producer cell line. This cell line (Clone 120C) was made in a variant of HEK293 and expresses all of the viral vector components from tetracycline-inducible promoters. 27 Upon tetracycline induction, this cell line produces viral vector particles at greater than 10 6 transducing units (TU)/ml. The particles from this cell line were tested for sensitivity to inactivation by serum from several human donors. We found that the stably produced particles were inactivated six-to 20-fold versus 14-to 50-fold for transiently produced vector particles in serum from the same four donors (data not shown). These data indicate that lentiviral vectors produced in a stable producer cell line are sensitive to complement inactivation, although to a slightly lesser degree than transiently produced vectors.
Lentiviral vectors show limited sensitivity to complement inactivation in serum from rodents and dogs
Thus far, there have been no published reports on the sensitivity of lentiviral vectors to serum complement from nonprimate species. Determination of vector sensitivity to complement from other species would serve the dual purpose of assessing the usefulness of an animal model for gene therapy studies and also identifying animal models where the problem of complement inactivation might be investigated. To determine the sensitivity of vectors to inactivation by animal sera, the survival of VSV-G-and Amphopseudotyped lentiviral vectors was measured following exposure to serum from rats, dogs and two strains of mice. The VSV-G-pseudotyped vectors were much less susceptible to inactivation by sera from these animal models as compared to human serum ( Figure 3a) . VSV-G vectors were resistant to serum from Swiss Nude mice. A slight reduction in titer of two-to three-fold was observed in serum from C57BL/6 mice and Nude rats. The vectors were moderately more sensitive to the canine serum, where the level of inactivation was four-to 10-fold. As with human serum, the Ampho-pseudotyped vectors once again proved to be more resistant to complement attack (Figure 3b ). No significant complement-dependent loss of Ampho titer was observed with the mouse or rodent sera. However, there was a small four-fold reduction in transducing activity following exposure to the serum from a single dog. In summary, the VSV-G-pseudotyped lentiviral vectors proved to be more resistant to animal serum than human serum with moderate sensitivity observed in canine serum.
Incorporation of CRPs into VSV-G-pseudotyped lentiviral vectors protects against human complement inactivation
The successful use of certain forms of CRPs to protect retroviral and baculoviral vectors from serum inactivation prompted the question of whether this approach might be useful for lentiviral vectors pseudotyped with VSV-G. 16, 28 To test this, VSV-G-pseudotyped vectors were prepared using the standard method of transient transfection (lacking supplementary CRPs) or with cotransfection of a fifth plasmid encoding one of three different CRPs. Using this method of expressing the complement regulator protein in the producer cells, it was anticipated that the membrane-associated proteins might be incorporated into the vector particles upon budding. The particles generated in the absence and presence of complement regulators were tested for sensitivity to inactivation by human serum from a number of individual donors. The most substantial protection of the vectors was achieved using the DAF/ CD55 complement inhibitor protein (Figure 4a ). With the standard VSV-G-pseudotyped vectors, we found the typical donor-dependent pattern of inactivation ( Figure  4a, left) . In contrast, VSV-G vectors generated via cotransfection of a DAF expression plasmid were almost completely resistant to human complement inactivation (VSV-G+DAF, right) in serum from identical donors. Whereas the vectors lacking supplemental DAF protein Figure 2 CH 50 complement activity in serum from individual human donors. Serum from 23 individual human donors was prepared from freshly drawn blood that was allowed to clot for several hours. Sera were aliquoted and stored frozen at À701C. For vector inactivation experiments, serum samples were thawed and split into two parts. One part was incubated at room temperature to retain normal complement activity, while the second part was heat inactivated at 561C for 1 h. The normal (hatched bars) and heat-inactivated serum samples (black bars) were tested for CH 50 complement activity using the Quidel CH 50 Eq Enzyme Immunoassay (donors 1-9, normal activity is any value over 70 U/ml) or the Diamedix E-Z CH50 assay (donors 10-23, normal activity is any value over 100 U/ml).
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showed three-to 50-fold reduction in titer, the particles prepared with DAF overexpressed in the producer cells showed a maximum of three-fold inactivation. The complement protection provided through expression of DAF/CD55 in the viral vector producer cells suggested that this protein was incorporated in the budded vector particles. To demonstrate that DAF/CD55 was incorporated into vector particles, VSV-G-pseudotyped vector particles made in the absence and presence of DAF/CD55 were immunoprecipitated with antibodies to VSV-G and DAF/CD55. ELISA analysis for p24
Gag was used to identify the bound viral vector particles. Whereas 61.5% of the starting p24 Gag protein in the reaction coprecipitated with the DAF/CD55 antibody if the particles were produced via coexpression of DAF/CD55, only 0.5% of the starting p24
Gag was recovered from particles generated in the absence of DAF/CD55 (Table 1 ). This Complement-resistant lentiviral vectors C Schauber-Plewa et al discrepancy in precipitated particles was specific to the antibody, however, because the VSV-G antibody captured similar percentages of the two vector types (11.6 versus 13.9%). Taken together, these data suggest that coexpression of the protein in the producer cells leads to the association of DAF/CD55 with p24-containing viral vector particles. VSV-G vectors made with MCP/CD46 complement inhibitor protein also showed some additional resistance to human complement. Figure 4b shows that MCP significantly protected the particles against destruction by serum from three out of five donors. In the same experiment, VSV-G particles with DAF incorporated did not show this donor-dependent effect, and protection was observed in serum from all five donors. Finally, it was found that CD59 did not appear to confer any significant protection to the lentivector particles, while DAF-containing particles in the same experiment were almost fully resistant (Figure 4c ). The lack of protection by CD59 was not due to lack of protein expression in the producer cells because antibody staining and FACS analysis confirmed an increase in surface CD59 levels in the transfected 293T cells (data not shown). Thus, the human complement-sensitive VSV-G vectors could be almost completely protected against inactivation through incorporation of DAF, while MCP had donor-dependent efficacy and CD59 showed little protection.
GP64-pseudotyped vector particles are also protected through DAF/CD55 incorporation
The ability to protect VSV-G-pseudotyped vectors from complement inactivation through DAF/CD55 incorporation prompted the question of whether DAF might also confer complement-resistance to baculovirus gp64-pseudotyped particles. gp64-pseudotyped lentivector particles were generated by transient transfection in the absence and presence of the DAF expression plasmid and then tested for human complement sensitivity. The standard gp64 vectors were inactivated 15-to 100-fold in serum from five individual human donors ( Figure 5 , left). In identical serum samples, gp64-pseudotyped particles with DAF incorporated were more resistant to inactivation. These vectors generated with the complement inhibitor protein were only inactivated two-to 16-fold, showing the particles to be at least five times more resistant in all serum samples ( Figure 5, right) . This result demonstrated the ubiquitous protecting ability of DAF and showed that lentiviral vectors with two distinct pseudotypes could be made complement-resistant using the same method.
Discussion
These studies demonstrated that VSV-G-and gp64-pseudotyped lentiviral vectors are susceptible to significant levels of inactivation by human serum complement (Figures 1a and c) . In contrast, Amphopseudotyped vectors from the same producer cells were almost completely resistant (Figure 1b) . This suggests that there may be epitopes intrinsic to the VSV-G or gp64 proteins that activate the complement cascade. Indeed, intact vesicular stomatitis virus shows comparable sensitivity to human serum inactivation and anti-VSV antibodies that could activate complement have been detected in human sera. 18, 19 We found that there was wide variation (almost three logs difference) in the ability of serum from individual human donors to inactivate the vectors pseudotyped with VSV-G. However, there was no strict correlation between the level of CH 50 complement activity in the sera and their level of VSV-G vector inactivation (Figure 2 ). The differences in levels of lentivector inactivation among individuals may be explained by donor variations in titer of VSV-G antibodies or some other absorbable factor as observed by DePolo et al. 6 Overall, these results suggest that the in vivo use of unaltered VSV-G-pseudotyped vectors (made via transient transfection or stable producer cell lines) in human patients would be problematic because of complement inactivation. In addition, the patient-topatient variation in vector sensitivity may complicate therapies by making treatment of some individuals more difficult than others.
An alternative explanation for VSV-G-and gp64-specific complement sensitivity is that budding of virus particles with these envelope glycoproteins may somehow exclude incorporation of host proteins such as CRPs that inhibit complement attack. This mechanism may explain the strong but less varied level of inactivation seen with gp64-pseudotyped particles, where individual human sera caused between 20-and 110-fold reductions in titer (a five-fold fluctuation as opposed to the several log fluctuation observed with VSV-G). It has not been determined if complement-fixing anti-gp64 antibodies can be found in human serum, although Hofmann and Strauss 15 showed that baculovirus vectors are inactivated by human complement via the classical pathway.
VSV-G-pseudotyped lentiviral vectors were not inactivated by nude mouse or nude rat serum, but serum from the immune-competent C57Bl/6 mice caused a slight reduction in titer. As in human serum, the Amphopseudotyped vectors were resistant to inactivation in all the rodent sera tested. The lack of vector inactivation in Figure 5 Lentiviral vectors pseudotyped with baculovirus gp64 are also protected by complement inhibitor incorporation. Concentrated preparations of lentiviral vectors carrying the GFP transgene and pseudotyped with the baculovirus gp64 envelope glycoprotein were generated in the absence (gp64) and presence of the DAF/CD55 complement inhibitor proteins (gp64+DAF) and tested for human complement inactivation as in Figure 1 . Bars represent the percentage of titer remaining in the vector samples after incubation with normal (hatched bars) or heat-inactivated serum (black bars) compared to vector incubated with the medium control (100%).
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C Schauber-Plewa et al the immune-deficient rodent serum may be caused by the athymic nature of these animals, in which Tlymphocytes are depleted. Alternatively, there may be other strain-related differences between the immunedeficient animals and the C57Bl/6 mice that affect the differential complement responses. In fact, anti-VSV IgM molecules have been detected in C57Bl/6 mice and may contribute to this response. 29 Regardless, the low-level vector inactivation caused by C57Bl/6 serum in vitro is probably not significant in vivo because VSV-G-pseudotyped vectors have been successfully used to transduce cells in these models following injection into the vasculature.
The complement-dependent inactivation of both VSV-G-and gp64-pseudotyped lentiviral vectors could be overcome by expressing CRPs in the producer cells. The expression of DAF/CD55 led to incorporation of the proteins into the vector particles as evidenced by the ability to immunoprecipitate those particles with an anti-DAF/CD55 antibody. Significantly, the CRP molecules were incorporated into the HIV vectors in an unmodified form. This finding is not surprising because it has been reported that HIV particles contain native DAF/CD55, MCP/CD46 and CD59 proteins. [30] [31] [32] [33] The ability to incorporate these proteins in the native conformation represents a critical advance for viral vector technology, since previous use of CRPs to protect MLV and baculovirus vectors required the generation of chimeric molecules with heterologous transmembrane domains for efficient incorporation. 16, 28 The formation of the chimeric CRPs was problematic because a number of chimeric forms of the molecules were not incorporated into the viral particles or caused reduced infectivity. 28 The incorporation of native CRPs into HIV vectors provides the novel advantage of complement-resistance without the trial and error of chimera generation and without negative effects on particle infectivity.
DAF was best able to protect the lentiviral vectors from human complement inactivation, with MCP providing protection against inactivation by serum from some donors. Spitzer et al 28 also found that DAF provided the best protection against human complement inactivation of Amphotropic retrovirus particles. The donor-dependent activity of MCP is not due to differences in the viral particles, because the same vector preparations were used for all of the reactions shown in Figure 4b . Therefore, the differential activity must reflect some variation in the donor sera, such as anti-VSV-G antibody titer. The varied level of protection in different donor sera might also reflect the possibility that these particles are inactivated through more than one mechanism or through different mechanisms in serum from individual donors. The more ubiquitous protecting ability of DAF might therefore be due to its ability to block complement activation through multiple mechanisms where MCP might only inhibit activation via one mechanism.
In contrast to the other CRPs, CD59 provided very little protection against complement inactivation. There was a few-fold protection of the VSV-G vector in the serum from one donor, but little protecting ability otherwise. The lack of activity may be due to poor incorporation of this protein into the vector particles in the transient production system. Alternatively, the CD59 protein may be incorporated but unable to protect against inactivation because its mechanism of action is at a distinct stage of the complement cascade that may not be required for lentivector inactivation. CD59 inhibits the final stage of complement activation comprising MAC formation and membrane lysis. 26 It has been suggested in other studies that virus particles may be inactivated by complement in a mechanism that does not require MAC formation, probably through particle aggregation or coating of the viral membrane with complement components that inhibit receptor binding or fusion. 9, 18 The results of these experiments demonstrate for the first time that complement-resistant lentiviral vectors can be readily produced through expression of unmodified CRP molecules in producer cells. This method of protection has been successfully used for vectors pseudotyped with diverse envelope glycoproteins, including VSV-G and baculovirus gp64. Unlike many other viral vectors, HIV-based vectors are amenable to being made complement-resistant because of their ability to incorporate native CRP molecules. This property is advantageous because there is no requirement for prior engineering of the complement regulator proteins. The ability to generate complement-resistant particles is yet another advantage for this technology and is an important advance toward the effective use of VSV-Gpseudotyped lentiviral vectors in human patients during gene therapy treatments.
Materials and methods

Plasmid constructs
The DAF/CD55, MCP/CD46 and CD59 genes were subcloned into a mammalian expression vector (pMD-2) 34 that carries a CMV promoter, a b-globin intron upstream of the open-reading frame (ORF) and a bglobin poly-A signal. The DAF ORF fragment was prepared by PCR amplification of the gene from ATCC IMAGE Consortium Clone #3317033 with the addition of EcoRI sites at each end. The primers used for amplification are as follows: forward primer, 5 0 -gcgaattcgccgccgc catgaccgtcgcgcggccg-3 0 (adds an EcoRI site and a Kozak consensus sequence upstream of the ATG); and reverse primer, 5 0 -gcgaattcctaagtcagcaagcccatgg-3 0 (adds an EcoRI site downstream of the stop codon). The MCP ORF fragment was prepared by PCR amplification of the gene from Stratagene GeneConnection Discovery Clone UniGene #Hs.83532 with the addition of EcoRI sites at each end. The primers used for amplification are as follows: forward primer, 5 0 -gcgaattcgccgccgccatg gagcctcccggccgc-3 0 (adds an EcoRI site and a Kozak consensus sequence upstream of the ATG); and reverse primer, 5 0 -gcgaattcctattcagcctctctgctctgc-3 0 (adds an EcoRI site downstream of the stop codon). The CD59 ORF fragment was prepared by PCR amplification of the gene from ATCC Clone #65964 (pK562-3) with the addition of EcoRI sites at each end. The primers used for amplification are as follows: forward primer, 5 0 -gcgaattcgccgccgc catgggaatccaaggaggg-3 0 (adds an EcoRI site and a Kozak consensus sequence upstream of the ATG); reverse primer, 5 0 -gcgaattcttagggatgaaggctccaggc-3 0 (adds an EcoRI site downstream of the stop codon). The PCR products were digested with EcoRI and ligated into EcoRI cut pMDLg/p.RRE to produce pMD2-DAF (pCG917), Complement-resistant lentiviral vectors C Schauber-Plewa et al pMD2-MCP (pCG918) and pMD2-CD59 (pCG919). The resulting plasmids were confirmed by sequencing.
Production of pseudotyped lentiviral vectors with and without complement inhibitor proteins by transient transfection
Third-generation HIV-1 vectors lacking complement inhibitor proteins were prepared by transient transfection according to published procedures 34 using a mixture of four plasmids in the following amounts per 10 cm dish: pMDLg/pRRE (Gag/Pol expression plasmid) at 6.5 mg, pRSV-Rev 34 at 2.5 mg, Transfer Vector (pRRL.sin.CMV.eGFP.ppt.pre or pRRL.sin.CM-V.eGFP.pre) 35 at 10 mg, and 3.5 mg of envelope plasmid (pMD2.VSVG-Env or pMD2.AcNPV.Env 3 or pMD2.Ampho.Env 36 ). For vectors with complement inhibitor proteins, a fifth plasmid (pMD2-DAF, pMD2-MCP or pMD2-CD59) was added to the transfection reaction at 10 mg per plate. Vector particles were harvested in conditioned medium in one 24-h collection. Vectors were concentrated by ultracentrifugation in a SW28 swinging bucket rotor at 19 500 r.p.m. for 2 h 20 min. Titer analysis and determination of p24
Gag concentration were performed as described previously. 34 
Determination of complement sensitivity
Serum samples were obtained from single human donors (Stanford Medical School Blood Center, Palo Alto, CA, USA), Beagle dogs (Covance, Berkeley, CA, USA), NIH Nude rats and from Swiss Nude and C57BL/6 mice (all from Taconic, Germantown, NY, USA). Sera were thawed and half of each serum sample was heated at 561C for 1 h to inactivate the complement. All sera were made by collecting fresh whole blood and allowing it to clot completely for several hours. Clots were pelleted by centrifugation and the serum supernatants were removed and frozen immediately in aliquots. CMV-GFP vector samples with different envelope pseudotypes were diluted to 10 6 TU/ml. A measure of 30-75 ml of the vector was diluted 1:5 into normal or heat-inactivated serum (or medium containing 10% heat-inactivated FBS as the no-serum control) and the mixture was incubated at 371C for 1 h. Following the incubation, medium was added to the reaction for an additional 1:5 dilution and then serially diluted twice at a 1:10 ratio and used to infect 293T cells in the presence of 8 mg/ml Polybrene for end point titer determination. The titer value was divided by the titer determined for the vector mixed with medium (the no-serum control) and reported as the percentage of recovery of titer compared to this control. All serum samples were analyzed for hemolytic complement activity (CH 50 ) using kits from Quidel (CH 50 Eq Enzyme Immunoassay; San Diego, CA, USA) or Diamedix (E-Z CH 50 ; Miami, FL, USA).
Immunoprecipitation of viral vector particles and p24
Gag determination
Samples of viral vector particles produced in the absence or presence of cotransfected CD55/DAF plasmid were filtered through a 0.45 mm CA filter. Immunoprecipitations were performed with 1 ml vector supernatant, 250 ml of 4 Â BupH Buffer (Pierce) and either 5 ml of anti-CD55/DAF antibody (Pharmingen) or 10 ml of anti-VSV-G antibody (Sigma). Tubes were incubated at 41C for 2 h with shaking. After the addition of 50 ml of Protein Aagarose beads (Pierce), the samples were incubated an additional 5 h at 41C. The beads were washed three times with 1 ml of PBS, resuspended in 200 ml PBS, and 10-fold serial dilutions were tested for p24 Gag concentration by ELISA (Perkin-Elmer).
